Bispecific BCMA-CD3 Antibodies Block Multiple Myeloma Tumor Growth

SIMPLE SUMMARY: Multiple myeloma accounts for approximately 10% of hematological cancers in the United States. It is a malignancy of plasma cells which accumulate in the bone marrow and produce a monoclonal protein. Novel treatments are needed to cure multiple myeloma patients. The goal of this repo...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Lijun, Huang, Yanwei, Sienkiewicz, John, Sun, Jinying, Guiang, Liselle, Li, Feng, Yang, Liming, Golubovskaya, Vita
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9139578/
https://www.ncbi.nlm.nih.gov/pubmed/35626122
http://dx.doi.org/10.3390/cancers14102518

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9139578/
https://www.ncbi.nlm.nih.gov/pubmed/35626122
http://dx.doi.org/10.3390/cancers14102518

Ejemplares similares